Halozyme Therapeutics (HALO) Return on Assets (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Return on Assets data on file, last reported at 0.0% in Q1 2026.

• On a quarterly basis, Return on Assets changed 0.0% year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.0%, a 0.0% change from a year earlier, with the FY2025 full-year figure at 0.0%, changed 0.0% from the prior year.
• Return on Assets for Q1 2026 stood at 0.0%, up from 0.0% in the prior quarter.
• Over the last five years, Return on Assets for HALO reached as high as 0.0% in Q1 2022 and fell as low as 0.0% in Q1 2023.
• Historically, Return on Assets has averaged 0.0% across 5 years, with a median of 0.0% in 2024.
• On a YoY basis, Return on Assets climbed as much as 0 bps in 2022 and fell as far as 0 bps in 2022.
• Year by year, Return on Assets stood at 0.0% in 2022, then jumped by 42 bps to 0.0% in 2023, then soared by 37 bps to 0.0% in 2024, then tumbled by 37 bps to 0.0% in 2025, then climbed by 1 bps to 0.0% in 2026.
• Per Business Quant data, the three most recent Return on Assets figures were 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.